GRAL
GRAIL, LLCNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$2.02B
P/E Ratio
—
EPS
$-11.11
Beta
—
52W High
$118.84
52W Low
$21.80
50-Day MA
$69.39
200-Day MA
$66.18
Dividend Yield
—
Profit Margin
-277.50%
Forward P/E
—
PEG Ratio
—
About GRAIL, LLC
GRAIL, LLC is a pioneering biotechnology firm focused on revolutionizing cancer detection through its state-of-the-art blood tests designed for early diagnosis. With its proprietary genomic technologies, GRAIL is at the forefront of the multi-cancer early detection (MCED) market, empowering individuals with essential information for proactive healthcare management. The company's dedication to advancing precision medicine not only aims to improve patient outcomes but also addresses critical gaps in cancer screening and diagnostics, positioning GRAIL as a crucial player in the future landscape of oncology.
Fundamentals
| Revenue (TTM) | $147.17M |
| Gross Profit (TTM) | $71.32M |
| EBITDA | $-377.85M |
| Operating Margin | -285.40% |
| Return on Equity | -16.10% |
| Return on Assets | -11.30% |
| Revenue/Share (TTM) | $4.00 |
| Book Value | $63.92 |
| Price-to-Book | 0.88 |
| Price-to-Sales (TTM) | 13.70 |
| EV/Revenue | 9.55 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 14.00% |
| Shares Outstanding | $41.02M |
| Float | $34.80M |
| % Insiders | 4.03% |
| % Institutions | 74.51% |
Analyst Ratings
Consensus ($72.40 target)
3
Buy3
HoldData last updated: 4/8/2026